Imaging Agent Able to Detect Early and Advanced Prostate Cancers by Tracking Biomarkers

Imaging Agent Able to Detect Early and Advanced Prostate Cancers by Tracking Biomarkers
A new imaging agent may hold promise in detecting both early prostate cancer and metastasis using PET/CT scans, according to data from a first-in-human trial. The agent, a radiolabeled dual-receptor, was shown to effectively track cancer cells, and have the potential to improve prostate cancer diagnosis and guide treatment decisions. The study, “Clinical Translation Of A Dual Integrin α3 And GRPR Targeting PET Radiotracer 68Ga-BBN-RGD,” was published in the Journal of Nuclear Medicine. "Although treatable at the early stage, prostate cancer is prone to metastasis," Xiaoyuan Chen, the study's senior author, said in a news release. "An effective and specific imaging method of detecting both primary and metastatic lesions is thus of critical importance to manage patients with prostate cancer." Researchers followed 13 men with prostate cancer (four new cases and nine post-therapy patients) and five healthy individuals to test the efficacy and safety of a compound called Ga-68-BBN-RGD. This agent is able to bind GRPR and integrin αvβ3 proteins, both of which are biomarkers of prostate cancer. The targeting of both proteins has the advantage of allowing tumor contrast when either or both biomarkers are present. "Compounds capable of targeting more than one biomarker have the ability of binding to both early and metastatic stages of prostate cancer, creating the possibility for a more prompt and accurate diagnostic profile for both primary and the metastatic tumors," Chen said. Participants underwent PET/CT scans 15 to
Subscribe or to access all post and page content.